Pharmaceuticals
China Jo-Jo Drugstores Hosts the First Suppliers Conference in China
HANGZHOU, China, Jan. 21, 2021 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that the...
2021-01-21 21:30
6939
Jemincare initiates phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody JMB2002
NANCHANG, China, Jan. 20, 2021 /PRNewswire/ -- On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002). Preclinical studies of JMB2002 including pharmacology and toxicity were ...
2021-01-20 13:53
1394
Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL
SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the Nati...
2021-01-19 19:30
3897
Neurophth and AAVnerGene Enter Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy
WUHAN, China and NEWARK, DE., Jan. 19, 2021 /PRNewswire/ -- Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy company (hereafter Neurophth), and AAVnerGene Inc., a specializing AAV technology company, today announced a strategic partnership to provide ...
2021-01-19 14:05
1520
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics' proprietary VELPTM platform to develop next-generation gene therapies. This new collaboration combines Boeh...
2021-01-18 22:00
2064
TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses, announced today that it ...
2021-01-18 21:00
1419
Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products
SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted the Medical Products Manuf...
2021-01-15 21:00
2906
ATIF Holdings Limited Announces Its IPO Client Soars 100% in the U.S. Trading Debut
LOS ANGELES, Jan. 13, 2021 /PRNewswire/ -- ATIF Holdings Limited (Nasdaq: ATIF, "ATIF"), a company providing business consulting and media services in Asia and North America, announces the client ofATIF, a China-based pharmaceutical and chemical products manufacturer, Qilian International Holding...
2021-01-13 21:00
9892
China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted approval fo...
2021-01-13 21:00
1636
Korea Fair Trade Commission Assigns Compliance Program Rating of "A" to Yuyu Pharma
SEOUL, South Korea, Jan. 11, 2021 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX: 000220) received Compliance Program (CP) Rating of "A" from the Korea Fair Trade Commission (FTC). Yuyu Pharma (Yuyu) established its CP team in 2016 with the help of the law firm Kim & Chang. The CP tea...
2021-01-11 22:00
4506
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
SHANGHAI, Jan. 9, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients inGreater China, announced today the closing of a$150 million Series B financing. The round...
2021-01-09 11:06
5644
Gracell Biotechnologies Announces Pricing of Initial Public Offering
SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical ne...
2021-01-08 14:55
9530
Bioworkshops successfully passed EU QP audit
SUZHOU, China, Jan. 6, 2021 /PRNewswire/ -- In November 2020, Bioworkshops passed a European drug Qualified Person audit (QP audit) for manufacture of clinical drug substance and drug product at their Suzhou site. The ratification of compliance to EU GMP comes within a month of obtaining a Drug M...
2021-01-06 22:00
1638
PharmAbcine to participate in BIO @ JPM and Biotech Showcase Digital during "J.P. Morgan Week 2021"
DAEJEON, South Korea, Jan. 4, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in BIO @ JPM and Biotech Showcase during the J.P. Morgan Wee...
2021-01-04 21:00
1708
ImmVira Announces Series C Financing with Leading Specialist Investors
SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C fina...
2020-12-31 19:29
3740
Yuyu Pharma was recognized as "Family-Friendly Company" by the Ministry of Gender Equality and Family
SEOUL, South Korea, Dec. 30, 2020 /PRNewswire/ -- Yuyu Pharma(CEO Robert Wonsang Yu, KRX: 000220) received recognition from the Ministry of Gender Equality and Family for implementing family-friendly policies for their employees. This is the second-time Yuyu has received this certification from ...
2020-12-30 22:00
2854
Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients
SHANGHAI, Dec. 25, 2020 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company with a leading portfolio of breakthrough technologies, announced on December 24th the clearance of the Investigational New Drug (IND) for Phase III trial of ARVN001 (triamcinolone acetonide s...
2020-12-25 21:00
3383
Foresee Pharmaceuticals Announces Completion of US$47 Million Financing
TAIPEI, Dec. 24, 2020 /PRNewswire/ -- Foresee pharmaceuticals (TPEx: 6576.TWO) ("Foresee") announces that it has successfully completed an underwritten public offering of 15,000,000 shares of its common stock to the public at a price of NT$88 per share. The aggregate gross proceeds to Foresee from...
2020-12-24 18:00
10546
Senhwa Biosciences Receives US FDA 'Study May Proceed' Letter to Treat BRCA2+ or PALB2+ Solid Tumors With CX-5461
TAIPEI and SAN DIEGO, Dec. 23. 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has received a "Study May Proceed" letter fr...
2020-12-24 10:40
2918
Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial
CHENGDU, China, Dec. 23, 2020 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong") announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, double-masked, parallel-gr...
2020-12-23 22:40
6379
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 293 media titles]
2025-01-13 10:44
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 286 media titles]
2025-01-14 21:00
VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20322
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6480
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5610
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4945
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4926
